INDUSTRY BRIEF: Healthcare stocks under pressure as national drug list expands
Many Hong Kong-listed drugmakers on Monday announced their products that were included in the 2025 edition of China’s National Reimbursement Drug List (NRDL), which was unveiled this week. The updated…
RELATED ARTICLES
-
Zai Lab under pressure over clinical results and rival drugs
9688.HKZLAB.US -
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
